292 related articles for article (PubMed ID: 17634485)
1. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
2. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
Reyno L; Seymour L; Tu D; Dent S; Gelmon K; Walley B; Pluzanska A; Gorbunova V; Garin A; Jassem J; Pienkowski T; Dancey J; Pearce L; MacNeil M; Marlin S; Lebwohl D; Voi M; Pritchard K;
J Clin Oncol; 2004 Jan; 22(2):269-76. PubMed ID: 14722035
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Lind PA; Naucler G; Holm A; Gubanski M; Svensson C
Acta Oncol; 2007; 46(2):230-3. PubMed ID: 17453374
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.
Stuart K; Tessitore J; Rudy J; Clendennin N; Johnston A
Cancer; 1999 Aug; 86(3):410-4. PubMed ID: 10430248
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma.
Mok TS; Leung TW; Lee SD; Chao Y; Chan AT; Huang A; Lui MC; Yeo W; Chak K; Johnston A; Johnson P
Cancer Chemother Pharmacol; 1999; 44(4):307-11. PubMed ID: 10447578
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Qin S; Bai Y; Lim HY; Thongprasert S; Chao Y; Fan J; Yang TS; Bhudhisawasdi V; Kang WK; Zhou Y; Lee JH; Sun Y
J Clin Oncol; 2013 Oct; 31(28):3501-8. PubMed ID: 23980077
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal Doxorubicin (lipo-dox).
Chen JR; Yang YC; Chen TC; Lai JC; Chang SJ; Chang CL; Wang KL
Taiwan J Obstet Gynecol; 2008 Sep; 47(3):322-6. PubMed ID: 18935997
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
17. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
[TBL] [Abstract][Full Text] [Related]
20. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Hong RL; Tseng YL
Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
